Clinical Trials
38 trialsNCT02286726 2026-06-04
CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03226418 2026-03-10
Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia
University of Nebraska
Phase 2 Completed
NCT03358719 2026-02-27
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT03995888 2026-02-12
Assessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer
Blue Earth Diagnostics
Phase 1 Completed
NCT04186845 2025-09-22
Spotlight
Blue Earth Diagnostics
Phase 3 Completed
NCT01290302 2025-06-12
Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza
American Regent, Inc.
Phase 1 Completed
NCT02257138 2025-06-08
Ruxolitinib Phosphate and Decitabine in Treating Patients With Relapsed or Refractory or Post Myeloproliferative Acute Myeloid Leukemia
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT04277442 2025-03-25
Testing Nivolumab in Combination With Decitabine and Venetoclax in Patients With Newly Diagnosed TP53 Gene Mutated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT04186819 2025-02-26
Imaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.
Blue Earth Diagnostics
Phase 3 Completed
NCT03092674 2025-01-16
Azacitidine With or Without Nivolumab or Midostaurin, or Decitabine and Cytarabine Alone in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
National Cancer Institute (NCI)
Phase 2/3 Completed
NCT03515538 2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2 Completed
NCT04028388 2024-04-17
ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer
Modra Pharmaceuticals
Phase 2 Completed
NCT01812252 2024-02-15
ICT-HCT
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT02653976 2024-01-26
A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Solasia Pharma K.K.
Phase 2 Completed
NCT01107626 2023-07-07
Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT04146038 2023-05-24
Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease
Rutgers, The State University of New Jersey
Phase 2 Completed
NCT02872701 2023-03-24
OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
On Target Laboratories, LLC
Phase 2 Completed
NCT04241315 2023-03-23
Elucidate
On Target Laboratories, LLC
Phase 3 Completed
NCT01420926 2023-02-28
Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01265849 2022-08-19
IT-MATTERS
CEL-SCI Corporation
Phase 3 Completed
NCT02317705 2022-06-21
Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer
On Target Laboratories, LLC
Phase 2 Completed
NCT03180307 2022-02-04
OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer
On Target Laboratories, LLC
Phase 3 Completed
NCT02136069 2021-12-03
GARDENIA
Hoffmann-La Roche
Phase 3 Completed
NCT02921061 2020-03-17
Decitabine With GCLAM for Adults With Newly Diagnosed, Relapsed, or Refractory AML or High-Risk MDS
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT00925782 2019-12-17
PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation
Acrotech Biopharma Inc.
Phase 2 Completed
NCT00416598 2019-02-19
Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT01729845 2019-02-07
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Fred Hutchinson Cancer Center
Phase 1/2 Completed
NCT02324335 2019-01-16
Brilacidin
Innovation Pharmaceuticals, Inc.
Phase 2 Completed
NCT02669615 2018-10-10
Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation
Medical College of Wisconsin
Phase 2 Completed
NCT01673022 2018-07-24
FIRES
Indiana University
Phase NA Completed
NCT01804101 2018-05-25
Liposomal Cytarabine-Daunorubicin CPX-351 in Treating Patients With Untreated Myelodysplastic Syndrome or Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase NA Completed
NCT02121418 2018-04-13
Decitabine and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia, High Risk Myelodysplastic Syndrome, or Myeloproliferative Neoplasm
University of Washington
Phase NA Completed
NCT02267083 2018-01-10
Efficacy and Safety Study of GPX-150 to Treat Soft Tissue Sarcoma
Gem Pharmaceuticals
Phase 2 Completed
NCT00711958 2017-09-05
Study to Assess the Efficacy and Safety of HX575 in the Treatment of Chemotherapy Associated Anemia in Cancer Patients
Sandoz
Phase 3 Completed
NCT00365872 2017-03-23
External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT02154139 2016-02-17
Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"
Takeda
Completed
NCT01314014 2016-01-06
ULYM11011
University of Rochester
Phase 2 Completed
NCT00918281 2014-06-09
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
Phase 2 Completed